17th May 2016
Roche Diagnostics continues to support local Sussex charity, with over £1700 raised from Midnight Walk
BURGESS HILL, UK (17 May 2016) – On 14th May employees from local company, Roche Diagnostics, took part in a 10 mile walk around Eastbourne taking in the beautiful sights of Sovereign Harbour and the seafront at night. Now in its seventh year, the annual ladies only sponsored walk raises money for Chestnut Tree House, a Sussex based charity that provides specialist care to children and young adults with life-threatening illnesses.
Alison Lingard, PA at Roche, said:
“It’s great to see so many people taking part in this year’s Midnight Walk. We all really enjoyed the walk and we are absolutely thrilled to have raised £1700 so far and we hope to raise even more”
Roche Diagnostics is continuing its programme to support the Sussex community following a successful year of fundraising over £15,000 in 2015 for Chestnut Tree House. The money raised will support the hospice’s mission to provide care and support for children with life-shortening illnesses, both at the hospice and in families’ own homes across East and West Sussex.
The charity of the year was voted for by Roche Diagnostics employees throughout UK and Ireland. The staff regularly put on a programme of fundraising events at their Burgess Hill office, as well as signing up individually for Chestnut Tree House’s programme of individual charity fundraising challenges to meet their fundraising goal.
- ENDS -
Notes to editor:
- Roche Diagnostics UK is based in Burgess Hill and employs approximately 600 people across the UK and Ireland.
- Roche Diagnostics have been based in Sussex for over 18 years.
For more information, please contact:
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.